Brokers Issue Forecasts for Charles River Laboratories Intl. Inc’s FY2018 Earnings (CRL)

Charles River Laboratories Intl. Inc (NYSE:CRL) – Jefferies Financial Group lifted their FY2018 earnings per share (EPS) estimates for shares of Charles River Laboratories Intl. in a note issued to investors on Wednesday, November 7th. Jefferies Financial Group analyst D. Windley now anticipates that the medical research company will post earnings of $5.92 per share for the year, up from their previous forecast of $5.89. Jefferies Financial Group currently has a “Buy” rating and a $145.00 target price on the stock. Jefferies Financial Group also issued estimates for Charles River Laboratories Intl.’s Q4 2018 earnings at $1.40 EPS, Q1 2019 earnings at $1.56 EPS, Q2 2019 earnings at $1.61 EPS, Q3 2019 earnings at $1.62 EPS, Q4 2019 earnings at $1.67 EPS, Q1 2020 earnings at $1.73 EPS, Q2 2020 earnings at $1.80 EPS, Q3 2020 earnings at $1.81 EPS and FY2020 earnings at $7.21 EPS.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 7th. The medical research company reported $1.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.38 by $0.15. Charles River Laboratories Intl. had a return on equity of 25.81% and a net margin of 6.39%. The company had revenue of $585.30 million during the quarter, compared to analysts’ expectations of $567.58 million. During the same quarter in the previous year, the business earned $1.30 earnings per share. The firm’s revenue for the quarter was up 26.1% on a year-over-year basis.

A number of other equities research analysts have also recently weighed in on the company. Robert W. Baird boosted their price objective on Charles River Laboratories Intl. from $144.00 to $148.00 and gave the company an “outperform” rating in a research note on Thursday. Raymond James boosted their price objective on Charles River Laboratories Intl. from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday. Royal Bank of Canada set a $147.00 price objective on Charles River Laboratories Intl. and gave the company a “buy” rating in a research note on Wednesday. ValuEngine cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Wednesday, October 24th. Finally, UBS Group began coverage on Charles River Laboratories Intl. in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $140.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Charles River Laboratories Intl. currently has an average rating of “Buy” and an average target price of $130.56.

Shares of NYSE CRL opened at $136.45 on Friday. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.72 and a quick ratio of 1.48. Charles River Laboratories Intl. has a twelve month low of $96.70 and a twelve month high of $138.89. The company has a market capitalization of $6.54 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.71 and a beta of 0.74.

In related news, insider David Ross Smith sold 1,249 shares of the company’s stock in a transaction on Monday, August 13th. The stock was sold at an average price of $120.05, for a total transaction of $149,942.45. Following the transaction, the insider now owns 13,690 shares of the company’s stock, valued at $1,643,484.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Deborah Turner Kochevar sold 4,066 shares of the company’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $123.66, for a total value of $502,801.56. Following the transaction, the director now directly owns 10,190 shares in the company, valued at approximately $1,260,095.40. The disclosure for this sale can be found here. Insiders have sold 28,671 shares of company stock valued at $3,829,160 in the last 90 days. Company insiders own 2.10% of the company’s stock.

A number of hedge funds have recently made changes to their positions in CRL. Principal Financial Group Inc. grew its holdings in Charles River Laboratories Intl. by 2.6% during the first quarter. Principal Financial Group Inc. now owns 207,753 shares of the medical research company’s stock worth $22,176,000 after acquiring an additional 5,293 shares during the period. Allianz Asset Management GmbH grew its holdings in Charles River Laboratories Intl. by 11.9% during the first quarter. Allianz Asset Management GmbH now owns 239,646 shares of the medical research company’s stock worth $25,579,000 after acquiring an additional 25,571 shares during the period. Xact Kapitalforvaltning AB grew its holdings in Charles River Laboratories Intl. by 26.5% during the second quarter. Xact Kapitalforvaltning AB now owns 7,637 shares of the medical research company’s stock worth $857,000 after acquiring an additional 1,600 shares during the period. Gateway Investment Advisers LLC acquired a new position in Charles River Laboratories Intl. during the second quarter worth $292,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Charles River Laboratories Intl. during the second quarter worth $270,000. 96.93% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: Day Trading – Risk Worth the Reward?

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply